Citizens Financial Group Inc RI cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,623 shares of the company’s stock after selling 831 shares during the quarter. Citizens Financial Group Inc RI’s holdings in Johnson & Johnson were worth $14,419,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $35,000. Retirement Financial Solutions LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $40,000. TD Capital Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the last quarter. 67.94% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Raymond James reduced their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Atlantic Securities dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Finally, Credit Suisse Group raised their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.67 EPS. On average, analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.00%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Warren Buffett Boosts Occidental Stake, Adds 3.46 Million Shares
- What’s Behind The Recent Meteoric Rise Of Tingo Group
- Is PulteGroup Overbought After Double-Digit Gains?
- Netflix Stock Just Had Its Largest Intraday Gain Since 2022
- Analyst Flags Concerns About P&G Growth Despite Earnings Beat
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.